Plain-English fact sheet
BPC-157
Also known as Body Protection Compound 157
BPC-157 is not FDA approved, and most published evidence is from animal or laboratory research rather than high-quality human trials.
Quick answer
BPC-157 is often promoted for injury or gut healing, but it is not an FDA-approved medicine and reliable human clinical evidence is extremely limited.
By the PeptideFactSheets Editorial Team. Use the source links to verify status, evidence, risks, and unknowns; our editorial policyexplains the boundaries. Clinician review appears only when a named reviewer is shown.
What is BPC-157?
BPC-157 is a synthetic sequence described as being derived from a gastric protein fragment.
Claims about healing are largely extrapolated from animal and laboratory studies, which cannot show that the same benefits or risks apply to people.
Why are people interested in it?
Online discussions frequently mention tendon, ligament, muscle, bone, nerve, and gastrointestinal recovery.
The gap between confident marketing and sparse human evidence is the central fact readers should understand.
Current regulatory status
BPC-157 is not FDA approved. A Phase 2 hamstring-strain trial is registered, and FDA lists BPC-157 among bulk substances for which compounded products may present significant safety risks and for which safety information is limited.
What is it approved for?
No FDA-approved use. This matters because clinical-trial participation and products marketed online are not the same as an approved medicine.
FDA approval path
Early human clinical testing
A Phase 2 hamstring-strain trial is registered, but no BPC-157 product is FDA approved and the published evidence base remains mostly preclinical.
Step 4 of 7
- DiscoveryBasic research
- PreclinicalLab and animal work
- Phase 1Initial human testing
- Phase 2Condition-focused trials
- Phase 3Confirmatory trials
- FDA reviewApplication review
- ApprovedLabel-specific use
What is it being studied for?
Investigational areas
- Acute hamstring-strain repair in a registered trial
- Preclinical models of tissue injury and gastrointestinal conditions
Evidence snapshot
Most cited work is preclinical. There is no mature body of randomized human trials establishing safety and effectiveness for common promoted uses.
Potential benefits being researched
- Animal and laboratory studies have reported signals related to tissue repair and inflammation.
- Those findings are hypotheses for human research, not proven patient benefits.
Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.
Known or possible risks
- Human short- and long-term safety are poorly characterized.
- FDA notes possible immune reactions, peptide-related impurities, and difficulty characterizing the active ingredient.
- Unapproved products may introduce contamination, incorrect-strength, sterility, or mislabeling risks.
What we still do not know
- Whether animal findings translate to meaningful human benefits
- Long-term safety, cancer-related signaling concerns, interactions, and reproductive risks
- A reliable adverse-effect rate or risk profile
- Whether products sold under the name consistently contain the claimed substance
Plain-English takeaway
BPC-157 is a striking example of online certainty outrunning human evidence. Preclinical findings are not a substitute for controlled trials or regulatory review.
Research and reference links
Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.
- 1fdaFDA: bulk substances that may present significant safety risks
FDA summaries of safety concerns and evidence gaps for selected bulk substances used in compounding.
- 2clinical trialsClinicalTrials.gov: BPC-157 hamstring strain study
Registry record for an early human BPC-157 study, not evidence of established clinical benefit.
- 3pubmedBPC-157 preclinical gastrointestinal review
Peer-reviewed review focused largely on preclinical BPC-157 research.
- 4pubmedBPC-157 wound-healing review
Review discussing BPC-157 wound-healing research, primarily outside mature human efficacy trials.